secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILE THERAPEUTICS INC (—)
CIK:        0001261249
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001558370-24-008293
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agile Therapeutics Q1 net revenue $5.7M (+58% QoQ); GAAP net income of $1.3M
----------------------------------------------------------------------------

- Net revenue $5.7M (+58% QoQ, +50% YoY); GAAP net income $1.3M ($0.28/share) vs. net loss $4.5M in Q4 2023.
- Twirla demand 81,088 cycles (+18% QoQ, +80% YoY); factory sales 70,662 cycles (+3% QoQ, +63% YoY).
- Operating expenses $6.8M (-20% YoY); cash $2.6M as of March 31, 2024.
- Stock now trading on OTC market under symbol AGRX; exploring strategic opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/0001558370-24-008293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1261249/000155837024008293/agrx-20240515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer